Abbonarsi

Nasal allergen challenge (NAC): Practical aspects and applications from an EU/US perspective—a Work Group Report of the AAAAI Rhinitis, Rhinosinusitis and Ocular Allergy Committee - 04/05/23

Doi : 10.1016/j.jaci.2023.02.014 
Seong H. Cho, MD a, b, Anil Nanda, MD c, d, Anjeni Keswani, MD e, Allen Adinoff, MD f, g, Fuad M. Baroody, MD h, Jonathan A. Bernstein, MD i, Alina Gherasim, MD, PhD j, Joseph K. Han, MD k, l, Jerald W. Koepke, MD f, g, Dennis K. Ledford, MD a, b, Amber N. Pepper, MD a, b, Carmen Rondón, MD, PhD m, Amy Schiffman, MD n, Martin Wagenmann, MD, PhD o, Paloma Campo, MD, PhD m,

the Rhinitis, Rhinosinusitis, and Ocular Allergy Committee of the AAAAI

a Division of Allergy and Immunology, Department of Internal Medicine, University of South Florida Morsani College of Medicine, Tampa, Fla 
b James A. Haley Veterans’ Affairs Hospital, Tampa, Fla 
c Asthma and Allergy Center, Lewisville and Flower Mound, Tex 
d Division of Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas, Tex 
e Division of Allergy/Immunology, George Washington University School of Medicine and Health Sciences, Washington, DC 
f Colorado Allergy and Asthma Centers, Denver, Colo 
g Department of Medicine, Division of Allergy and Immunology, University of Colorado, Denver, Colo 
h Section of Otolaryngology—Head and Neck Surgery, University of Chicago, Chicago, Ill 
i Department of Internal Medicine, Division of Rheumatology, Allergy and Immunology, University of Cincinnati, Cincinnati, Ohio 
j ALYATEC Environmental Exposure Chamber, Strasbourg, France 
k Division of Rhinology and Endoscopic Sinus Surgery, Department of Otolayrngology—Head and Neck Surgery, Eastern Virginia Medical School, Norfolk, Va 
l Divison of Allergy, Department of Otolayrngology—Head and Neck Surgery, Eastern Virginia Medical School, Norfolk, Va 
m Allergy Unit, Hospital Regional Universitario de Málaga, Instituto de Investigacion Biomedica de Malaga (IBIMA), Red de Asma, Reacciones Adversas a Farmacos y Alergia (ARADyAL), Málaga, Spain 
n Allergy, Asthma, and Immunology Specialists, Boca Raton, Fla 
o Department of Otorhinolaryngology, Düsseldorf University Hospital, Düsseldorf, Germany 

Corresponding author: Paloma Campo, MD, PhD, Allergy Unit, University Hospital of Málaga, Plaza Hospital Civil, s/n Málaga, Spain 29009.Allergy UnitUniversity Hospital of MálagaPlaza Hospital Civils/n Málaga29009Spain

Abstract

Nasal allergen challenge (NAC) is applied in a variety of settings (research centers, specialty clinics, and hospitals) as a useful diagnostic and research tool. NAC is indicated for diagnosis of seasonal and perennial allergic rhinitis, local allergic rhinitis, and occupational rhinitis; to design the composition of allergen immunotherapy in patients who are polysensitized; and to investigate the physio-pathological mechanisms of nasal diseases. NAC is currently a safe and reproducible technique, although it is time- and resource-consuming. NAC can be performed by a variety of methods, but the lack of a uniform technique for performing and recording the outcomes represents a challenge for those considering NAC as a clinical tool in the office. The availability of standardized allergens for NAC is also different in each country. The objective of this workgroup report is to review the current information about NAC, focusing on the practical aspects and application for diagnosis of difficult rhinitis phenotypes (eg, local allergic rhinitis, occupational rhinitis), taking into account the particular context of practice in the United States and the European Union.

Il testo completo di questo articolo è disponibile in PDF.

Key words : Allergen, challenge, nasal, obstruction, symptoms

Abbreviations used : AIT, AR, EAACI, ENT, FDA, HC, HEP, HMW, LAR, LMW, NAC, NAR, NO, OA, OR, PNIF, RNM, sIgE, SPT, TNSS, VAS


Mappa


 Disclosure of potential conflict of interest: S.H. Cho reports grant support from Sanofi/Regeneron. C. Rondon reports grant and personal fees from ALK-Abelló, and personal fees from Allergopharma, LETI Pharma, Teva Pharmaceuticals, and Novartis. J.K. Han has served on scientific advisory boards for ALK-Abelló. D.K. Ledford reports research grants from AstraZeneca and Novartis; consultant fees from BioCryst, GSK, and AstraZeneca; and speaker fees from AstraZeneca, GSK, Genentech, Teva Pharmaceuticals, Sanofi/Regeneron, and MedImmune. A.N. Pepper reports grant support from Regeneron Pharmaceuticals, Pfizer, Aimmune Therapeutics, Alladapt Immunotherapeutics, ARS Pharma, Biocryst Pharmaceuticals, GENENTECH, Inc, IgGenix, Kalvista Pharmaceuticals, Novartis, Sanofi, Stallergenes Greer, Takeda Pharmaceutical Company, Gilead, and Molekule Inc. M. Wagenmann reports grants from Takeda; grants and personal fees from ALK-Abelló, AstraZeneca, GSK, Novartis, and Sanofi Aventis; and personal fees from Allergopharma, Bencard, Genzyme, Infectopharm, LETI Pharma, med update, and Stallergenes. The rest of the authors declare that they have no relevant conflicts of interest.


© 2023  American Academy of Allergy, Asthma & Immunology. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 151 - N° 5

P. 1215 - Maggio 2023 Ritorno al numero
Articolo precedente Articolo precedente
  • Autoimmune manifestations in VEXAS: Opportunities for integration and pitfalls to interpretation
  • Alessandro Bruno, Carmelo Gurnari, Tobias Alexander, John A. Snowden, Raffaella Greco, Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation
| Articolo seguente Articolo seguente
  • The Editors’ Choice

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.